Our Science
Approximately 90% of disease-causing proteins are not drugged, or are inadequately drugged due to limitations with traditional small molecules that target the active site of a protein.
Atavistik leverages allostery to identify novel opportunities for therapeutic intervention and develop differentiated medicines that target the underlying biology of disease.
By leveraging our novel allosteric drug discovery platform, we are advancing a pipeline of hematology therapeutics designed to address significant unmet medical needs, including hereditary hemorrhagic telanglectasia (HHT).

———
Harnessing Allostery to Address the Underlying Biology of Disease
We are harnessing the power of allostery to address unmet patient needs.
Allostery enables novel approaches to challenging disease-driving targets.
Our platform identifies biologically relevant allosteric binding sites that can support the development of highly selective therapeutics.
The discovery of novel allosteric binding sites enables the efficient development of differentiated therapies with the potential to address significant unmet medical needs.
By leveraging the body’s natural regulators, we efficiently and systematically uncover functional allosteric pockets across a broad range of target classes (e.g., transcription factors, membrane proteins, large complexes).
Our Platform
Our platform identifies novel allosteric binding sites that enable the discovery and development of differentiated hematology therapeutics.
![]() |
![]() |
![]() |
![]() |
![]() |
| Proprietary AMPS screening technology repeatedly identifies functional allosteric binders | Novel cryptic binding pockets enable rapid and efficient AI/ML driven structure-based drug design and chemistry | Structure-based drug design supports rapid improvements in potency to generate differentiated therapeutics |
Therapeutic Approach
Our allosteric development platform supports the discovery of differentiated therapeutic approaches against challenging disease-driving targets. Insights generated through the platform have enabled the advancement of our internal pipeline focused on rare hematologic diseases, including hereditary hemorrhagic telangiectasia (HHT).
Beyond our internal programs, we believe the broad applicability of allosteric biology creates opportunities for strategic partnerships aimed at advancing innovative therapies across additional therapeutic areas.



